Experts convened in Cleveland, Ohio, on November 11, 2025, to discuss the evolution of cardio-renal-metabolic care from ...

Nerandomilast, a novel anti-fibrotic agent with improved tolerability and a dual antifibrotic/immunomodulatory mechanism, ...

AI's role in early cancer detection and patient outcome improvement is significant, with tools evaluated for utility and ...

Guidelines statement on biosimilars was revised to include any appropriate biosimilar for a therapy vs focusing on rituximab.

A central challenge in relapsed/refractory follicular lymphoma is determining a treatment sequence that maximizes current ...

Nerandomilast's tolerability and dual antifibrotic/immunomodulatory mechanism directly address the critical non-adherence ...

Panelists discuss how improving adherence to LDL-lowering therapies is essential for sustained cardiovascular protection.

This retrospective analysis is published in Naunyn-Schmiedeberg's Archives of Pharmacology.

Panelists discuss how long-term LDL-C exposure heightens cardiovascular risk, making early and sustained lowering crucial.

The ZENITH trial showed sotatercept significantly reduced death, transplant, or hospitalization risk in advanced PAH, leading ...

Self-insured employers face legal challenges in adopting value-based models, including ERISA fiduciary duties, HIPAA restrictions, and antitrust concerns. Standardized data definitions and performance ...

Value-based care adoption in employer insurance requires replacing fragmented point solutions with unified, at-risk performance contracts that align vendors, providers, and members around total cost ...